SCHEMBL160689

SCHEMBL160689

CC(OC(=O)c1ccc(O)cc1)Oc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.59
CA1 P00915 3/20 0.59
CA2 P00918 3/20 0.59
CA7 P43166 3/20 0.59
CA9 Q16790 3/20 0.59
CA14 Q9ULX7 3/20 0.59
ESR1 P03372 3/20 0.57
ESR2 Q92731 3/20 0.57
PDCD1 Q15116 1/20 0.50
CD274 Q9NZQ7 1/20 0.50
ALDH1A1 P00352 4/20 0.47
LMNA P02545 4/20 0.46
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TP53 P04637 1/20 0.43
TSHR P16473 1/20 0.43
MTNR1A P48039 1/20 0.43
MTNR1B P49286 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11323594 0.93 PDCD1 (0.56) CA12CA1CA2CA7CA9
SCHEMBL4923900 0.90 TSHR (0.53) CA12CA1CA2CA7CA9
SCHEMBL11323607 0.89 KMT2A (0.56) CA12CA1CA2CA7CA9
SCHEMBL5152870 0.86 CA12 (0.67) CA12CA1CA2CA7CA9
SCHEMBL10885498 0.86 PDCD1 (0.49) CA12CA1CA2CA7CA9
Isopropyl 4-Hydroxybenzoate SCHEMBL4729205 0.83 CA12 (0.68) CA12CA1CA2CA7CA9
SCHEMBL18297774 0.80 TSHR (0.57) LMNANPC1RAB9ATP53TSHR
SCHEMBL11327383 0.80 TSHR (0.48) ALDH1A1LMNANPC1HTTTP53
SCHEMBL7172794 0.79 CA12 (0.63) CA12CA1CA2CA7CA9
Paraben SCHEMBL28070554 0.79 KMT2A (0.45) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 499 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230363380-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF WILSON JOHN PAUL (US) 2023-11-16 US claimed
US-20220079145-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF WILSON JOHN PAUL (US) 2022-03-17 US claimed
US-20180077925-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF WILSON JOHN PAUL (US) 2018-03-22 US claimed
EP-3265135-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF Wilson, John Paul (US) 2018-01-10 EP claimed
WO-2016144907-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF WILSON JOHN PAUL (US) 2016-09-15 WO claimed
EP-1613302-B1 PRESERVED AND STABLE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND METHODS RELATED THERETO PROCYTE CORP (US) 2009-12-23 EP claimed
EP-1793871-A2 NON-ABSORBENT AND ABSORBENT ARTICLES FOR INHIBITING THE PRODUCTION OF EXOPROTEINS Kimberly-Clark Worldwide, Inc. (US) 2007-06-13 EP claimed
US-7128923-B2 Preserved and stable compositions containing peptide copper complexes and method related thereto PROCYTE CORPORATION (US) 2006-10-31 US claimed
WO-2006038980-A2 NON-ABSORBENT AND ABSORBENT ARTICLES FOR INHIBITING THE PRODUCTION OF EXOPROTEINS KIMBERLY-CLARK WORLDWIDE, INC. (US) 2006-04-13 WO claimed
US-20060067990-A1 Absorbent articles for inhibiting the production of exoproteins KIMBERLY-CLARK WORLDWIDE, INC. 2006-03-30 US claimed
US-6897281-B2 Breathable polyurethanes, blends, and articles NOVEON IP HOLDINGS CORP. (US) 2005-05-24 US claimed
WO-1994012115-A1 PROTECTIVE MEDICAL GLOVE AND ANTIBACTERIAL/ANTIPERSPIRANT COMPOSITION FOR REDUCING BACTERIAL GROWTH DURING USE OF MEDICAL GLOVES BUCHANAN, INC. (US) 1994-06-09 WO claimed
US-20260062580-A1 REVERSIBLY THERMOCHROMIC COMPOSITION, REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT ENCAPSULATING REVERSIBLY THERMOCHROMIC COMPOSITION, AND WRITING INSTRUMENT USING REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT THE PILOT INK CO., LTD. (JP) 2026-03-05 US disclosed
EP-3592329-B1 USE OF COMPATIBLE SOLUTES SUSONITY Commercial GmbH (DE) 2026-02-18 EP disclosed
US-20260041615-A1 FOAMING MIXED ALCOHOL/WATER COMPOSITIONS COMPRISING A STRUCTURED ALKOXYLATED SILOXANE ECOLAB USA INC (US) 2026-02-12 US disclosed
EP-4340807-B1 HAIR COLOR COMPOSITIONS FOR MITIGATING COLOR LOSS LUBRIZOL ADVANCED MAT INC (US) 2026-01-28 EP disclosed
WO-1994012115-A1 PROTECTIVE MEDICAL GLOVE AND ANTIBACTERIAL/ANTIPERSPIRANT COMPOSITION FOR REDUCING BACTERIAL GROWTH DURING USE OF MEDICAL GLOVES BUCHANAN, INC. (US) 1994-06-09 WO disclosed
US-5053219-A Colloids of calcium phosphocasinate, low lactose concentration; natural appearance, storage stability RHONE-ELECTRA S.A. (CH) 1991-10-01 US disclosed
WO-1991013617-A1 ANTIMICROBIAL PRESERVATIVE SYSTEM COMPRISING A FORMALDEHYDE SUBSTITUTED HYDANTOIN THE MCINTYRE GROUP, LTD. (US) 1991-09-19 WO disclosed
US-5037843-A Cold stability-anhydrous liquid; containing polyhydroxy alcohol solvent and alkalizing agent THE MCINTYRE GROUP, LTD. (US) 1991-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062580-A1 REVERSIBLY THERMOCHROMIC COMPOSITION, REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT ENCAPSULATING REVERSIBLY THERMOCHROMIC COMPOSITION, AND WRITING INSTRUMENT USING REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT TYR, SCO2, HBB CA12 3080/4885CA1 4057/4885CA2 1535/4885
US-20060067990-A1 Absorbent articles for inhibiting the production of exoproteins SLC43A1, MRPL21, SLC7A5 CA12 3078/4885CA1 3676/4885CA2 1846/4885
US-20260041615-A1 FOAMING MIXED ALCOHOL/WATER COMPOSITIONS COMPRISING A STRUCTURED ALKOXYLATED SILOXANE SMURF1, SMURF2, ALKBH3 CA12 3622/4885CA1 3920/4885CA2 4311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.